Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study.

Kondo Y, Satoh S, Terauchi Y

Diabetology international3 Apr 2024Cited by 7 (Europe PMC)

PMID39101164PMCIDPMC11291836DOI10.1007/s13340-024-00717-6PepBankPUB-39101164

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, disposition index change did not differ between dulaglutide and trelagliptin.
In plain wordsIn patients with diabetes, the change in disposition index did not differ between dulaglutide and trelagliptin.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeDisposition index change
Study
n = 48
Comparator
Trelagliptin 100 mg/week
Analysis
Primary
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.75 mg/week · 24 weeksAs given in this study (human).
Measurements
Disposition index change
−0.07 index
dulaglutide
Disposition index change
0.59 index
trelagliptin
Source sentences
Summary
Change in disposition index during the 24 weeks did not differ between the groups (dulaglutide: - 0.07 ± 1.08 vs. trelagliptin: + 0.59 ± 1.04; p = 0.66),
4 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the change in disposition index over the 24-week treatment period.
Summary · context
This randomized, open-label, parallel-group, controlled trial compared the effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes.
Summary · context
For 24 weeks, participants received dulaglutide (0.75 mg/week) or trelagliptin (100 mg/week), after which beta-cell function was evaluated using a glucagon stimulation test-based disposition index.
Summary · context
Forty-eight patients completed the 24-week dulaglutide (n = 23) or trelagliptin (n = 25) treatment.
Report a problemFND-3910116402
02HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide reduced HbA1c more than trelagliptin.
In plain wordsIn patients with diabetes, dulaglutide lowered long-term blood sugar more than trelagliptin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n = 48
Comparator
Trelagliptin 100 mg/week
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg/week · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−0.77%
dulaglutide
HbA1c change
−0.57%
trelagliptin
Source sentences
Summary
The dulaglutide group reduced HbA1c levels more than the trelagliptin group (dulaglutide: - 0.77% ± 0.07% vs. trelagliptin: - 0.57% ± 0.07%; p = 0.04).
3 context sentences(design, population, supporting numbers)
Summary · context
This randomized, open-label, parallel-group, controlled trial compared the effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes.
Summary · context
For 24 weeks, participants received dulaglutide (0.75 mg/week) or trelagliptin (100 mg/week), after which beta-cell function was evaluated using a glucagon stimulation test-based disposition index.
Summary · context
Forty-eight patients completed the 24-week dulaglutide (n = 23) or trelagliptin (n = 25) treatment.
Report a problemFND-3910116401
03HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide increased HOMA2-%β more than trelagliptin.
In plain wordsIn patients with diabetes, dulaglutide increased a measure of insulin-producing cell function more than trelagliptin.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHOMA2-%β change
Study
n = 48
Comparator
Trelagliptin 100 mg/week
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
0.75 mg/week · 24 weeksAs given in this study (human).
Measurements
HOMA2-%β change
26.2%
dulaglutide
HOMA2-%β change
5.4%
trelagliptin
Source sentences
Summary
but the dulaglutide group increased HOMA2-%β levels more than the trelagliptin group (dulaglutide: + 26.2 ± 4.3% vs. trelagliptin: + 5.4 ± 4.1%; p = 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This randomized, open-label, parallel-group, controlled trial compared the effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes.
Summary · context
For 24 weeks, participants received dulaglutide (0.75 mg/week) or trelagliptin (100 mg/week), after which beta-cell function was evaluated using a glucagon stimulation test-based disposition index.
Summary · context
Forty-eight patients completed the 24-week dulaglutide (n = 23) or trelagliptin (n = 25) treatment.
Report a problemFND-3910116403
04HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, dulaglutide reduced body fat mass more than trelagliptin.
In plain wordsIn patients with diabetes, dulaglutide reduced body fat more than trelagliptin.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody fat mass change
Study
n = 48
Comparator
Trelagliptin 100 mg/week
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg/week · 24 weeksAs given in this study (human).
Measurements
Fat mass change
−1.2 kg
dulaglutide
Fat mass change
−0.3 kg
trelagliptin
Source sentences
Summary
The dulaglutide group showed greater body fat mass reduction than the trelagliptin group (dulaglutide: - 1.2 ± 0.3 kg vs. trelagliptin: - 0.3 ± 0.2 kg; p = 0.02) without skeletal muscle mass loss.
3 context sentences(design, population, supporting numbers)
Summary · context
This randomized, open-label, parallel-group, controlled trial compared the effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes.
Summary · context
For 24 weeks, participants received dulaglutide (0.75 mg/week) or trelagliptin (100 mg/week), after which beta-cell function was evaluated using a glucagon stimulation test-based disposition index.
Summary · context
Forty-eight patients completed the 24-week dulaglutide (n = 23) or trelagliptin (n = 25) treatment.
Report a problemFND-3910116404
05HumanRandomized controlled trialEfficacy outcome
In patients with diabetes, skeletal muscle mass did not decrease during dulaglutide treatment.
In plain wordsIn patients with diabetes, skeletal muscle mass did not decrease during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSkeletal muscle mass loss
Study
n = 23
Outcome group
Body weight · Musculoskeletal
Studied dose
0.75 mg/week · 24 weeksAs given in this study (human).
Source sentences
Summary
The dulaglutide group showed greater body fat mass reduction than the trelagliptin group (dulaglutide: - 1.2 ± 0.3 kg vs. trelagliptin: - 0.3 ± 0.2 kg; p = 0.02) without skeletal muscle mass loss.
3 context sentences(design, population, supporting numbers)
Summary · context
This randomized, open-label, parallel-group, controlled trial compared the effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes.
Summary · context
For 24 weeks, participants received dulaglutide (0.75 mg/week) or trelagliptin (100 mg/week), after which beta-cell function was evaluated using a glucagon stimulation test-based disposition index.
Summary · context
Forty-eight patients completed the 24-week dulaglutide (n = 23) or trelagliptin (n = 25) treatment.
Report a problemFND-3910116405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.